On June 15, 2022, Zinwi Bio-Tech became one of the first vape-industry companies to secure the production license for electronic cigarettes (e-liquid category) issued under new measures introduced by the Chinese government to bring e-cigarettes under tobacco regulations.
The State Tobacco Monopoly Administration of China (STMA) passed the Electronic Cigarette Administration Measures (Measures) on March 11, 2022, with the Measures becoming effective from May 1.
Under the Measures, a production license issued by the STMA is a pre-condition for the incorporation of a company involved in the manufacture of e-cigarette products, e-atomization materials (i.e. e-liquids) or e-cigarette nicotine.
To secure the license, a company must prove that has sufficient funds for production, with adequate facilities and equipment to meet the set standards.
The materials and information required to submit an application are wide ranging and cover topics including financial status, production process and quality management.
In addition, the time-window for submitting applications is narrow – they must be completed between May 5, and September 30, 2022.
Moreover, the bar is set very high to ensure a sufficient standard is reached by those applying. The STMA not only review the application materials very thoroughly but they also conduct very strict on-site checks as part of the process.
Zinwi Bio-Tech was very prompt in presenting its application but it was diligent and thorough so that the company was able to pass all of the requirements and screening procedures required by the new Measures.
This meant that Zinwi Bio-Tech was successful in being amongst the first batch of companies to receive the e-cigarette manufacturer licenses, indicating its strong status in the industry.
Shenzhen Zinwi Bio-Tech Co., Ltd (Zinwi Bio-Tech) was established in 2016 and has its headquarters in Guangming District, Shenzhen. It is a high-tech enterprise integrating the R&D, production and sales of e-liquid, having developed into a global leader in the e-liquid solution service sector. In 2021, Zinwi Bio-Tech’s annual e-liquid shipment reached over 2,000 tonnes, equivalent to approximately 1.3 billion pods.
Product R&D, technological innovation and strict quality control are central to Zinwi Bio-Tech, with a strong focus on harm reduction atomization technology. An atomization technology research institute, led by a doctoral team, was established in 2020; the R&D team continually break through the industry’s technical barriers, and has obtained and applied for over 200 patents. The company’s team of professional flavour chemists has developed tens of thousands of e-liquid product formulas.
Commitment to quality is supported by numerous accreditations including ISO9001 quality system, national CNAS laboratory and GMP certifications, amongst others. Products are exported to countries across Europe, America and Canada, the Middle East, Russia and more, and have been recognized by over 300 brand customers.
Zinwi Bio-Tech is committed to a mission of ‘leading the vaping industry and leading a healthy lifestyle’ and aims to always be at the forefront of the global e-liquid solution service industry.
